CureVac vs Pfizer

CureVac and Pfizer are two pharmaceutical companies at the forefront of developing vaccines to combat the COVID-19 pandemic. CureVac, a biopharmaceutical company based in Germany, has been working on developing an mRNA-based vaccine similar to the one created by Pfizer. Both companies have seen fluctuations in their stock prices due to their involvement in the vaccine race. Investors are closely monitoring the progress of these companies as the global demand for effective vaccines continues to grow.

CureVac or Pfizer?

When comparing CureVac and Pfizer, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between CureVac and Pfizer.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. CureVac has a dividend yield of -%, while Pfizer has a dividend yield of 5.67%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. CureVac reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Pfizer reports a 5-year dividend growth of 4.08% year and a payout ratio of -360.95%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with CureVac P/E ratio at -2.09 and Pfizer's P/E ratio at -64.18. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. CureVac P/B ratio is 1.54 while Pfizer's P/B ratio is 1.90.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, CureVac has seen a 5-year revenue growth of 2.26%, while Pfizer's is 0.13%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with CureVac's ROE at -56.93% and Pfizer's ROE at -2.84%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $2.79 for CureVac and $29.09 for Pfizer. Over the past year, CureVac's prices ranged from $2.21 to $6.30, with a yearly change of 184.42%. Pfizer's prices fluctuated between $25.20 and $33.19, with a yearly change of 31.71%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.